Compare Charles River Laboratories Intl. Inc (CRL) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Toyota Motor Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Toyota Motor Corp trades at $185.7 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 15.3× Charles River Laboratories Intl. Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Toyota Motor Corp for 116 Days on average.
| CRL | TM | |
|---|---|---|
Market Cap | $14.23B | $217.38B |
Volume | 1,176,885 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $248.29 |
52-Week Low | $149.93 | $166.50 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $17.06B | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while consistently beating earnings expectations in recent quarters. Recent news highlights Toyota's growing U.S. market share and electrification progress with 37.8% growth in EV sales. Cash flow trends show improvement with projected 2026 operating cash flow of $4.13T.
Toyota presents a value opportunity with solid profitability and market positioning, though near-term technical weakness and China sales challenges warrant caution. The company's hybrid technology leadership and North American expansion provide growth catalysts, while analyst consensus leans neutral with 62.5% hold ratings. Debt levels remain manageable at 41.29% debt-to-asset ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
